Abstract
Since early 2022, Omicron BA.1 has been eclipsed by BA.2, which was in turn outcompeted by BA.5, that displays enhanced antibody escape properties. Here, we evaluated the duration of the neutralizing antibody (Nab) response, up to 16 months after Pfizer BNT162b2 vaccination, in individuals with or without BA.1/BA.2 breakthrough infection. We measured neutralization of the ancestral D614G lineage, Delta and Omicron BA.1, BA.2, BA.5 variants in 291 sera and 35 nasal swabs from 27 individuals. Upon vaccination, serum Nab titers were reduced by 10-, 15-and 25-fold for BA.1, BA.2 and BA.5, respectively, compared with D614G. The duration of neutralization was markedly shortened, from an estimated period of 11.5 months post-boost with D614G to 5.5 months with BA.5. After breakthrough, we observed a sharp increase of Nabs against Omicron subvariants, followed by a plateau and a slow decline after 4-5 months. In nasal swabs, infection, but not vaccination, triggered a strong IgA response and a detectable Omicron neutralizing activity. Thus, BA.5 spread is partly due to abbreviated vaccine efficacy, particularly in individuals who were not infected with previous Omicron variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Work in OS lab is funded by: Institut Pasteur Urgence COVID-19 Fundraising Campaign of Institut Pasteur Fondation pour la Recherche Medicale (FRM) ANRS Vaccine Research Institute (ANR10LABX77) Labex IBEID (ANR10LABX62IBEID) ANR/FRM Flash Covid PROTEOSARSCoV2 ANR Coronamito and IDISCOVR. DP is supported by the Vaccine Research Institute. Work in OS lab is funded by: Institut Pasteur INCEPTION program (Investissements Avenir grant ANR16CONV0005) The French Government Investissement Avenir programme Laboratoire Excellence Integrative Biology of Emerging Infectious Diseases (grant no. ANR10LABX62IBEID) NIH PICREID (grant no U01AI151758). The Opera system was cofunded by Institut Pasteur and the Region ile de France (DIM1Health). Work in UPBI is funded by: grant ANR10INSB0401 Region Ile de France program DIM1 Health. The funders of this study had no role in study design data collection and analysis and interpretation or writing of the article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study NCT04750720 was approved by the Ile de France IV ethical committee. At enrollment, written informed consent was collected and participants completed a questionnaire covering sociodemographic characteristics, virological findings (SARSCoV2 RTqPCR results, date of testing) and data related to SARSCoV2 vaccination (brand product, date of first, second and third vaccination).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-last authors
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding authors.
